Company intelligence / Profile preview

InterK Peptide Therapeutics

Sydney, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

Lead peptides have demonstrated proof-of-concept results with inhibition of cancer growth in animal models, immune system modulation (Th1 response, selective Lck activation), and have shown immunomodulatory effects in human and mouse immune cells; partnerships with academic and CRO collaborators have strengthened IP and investment prospects

Therapeutic areas: ImmunologyInfectious DiseasesDermatologyOncologyNeurology
Modalities: PeptidesSynthetic peptidesPeptide-drug conjugate
Industry: Biotech

Drug pipeline

4 assets

IK14004

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Concept Life SciencesMalvern Panalytical

Beyond the preview

Go deeper on InterK Peptide Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InterK Peptide Therapeutics.

Explore the full profile